GlassScriptPhysician profile
Anika Ross
NPI 1669966396
$1,954.45
in general payments reported to CMS, 2019-2025
21 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $806 · 2024: $580 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.47 |
| Education | $384.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $391.62 | 2023-2025 | Lifevest |
| Abbott Laboratories | $331.81 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Quadra Assura |
| Amgen INC. | $158.82 | 2023-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $152.44 | 2023-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $151.52 | 2024-2025 | Farxiga |
| Shockwave Medical, INC | $137.63 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.48 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $76.23 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $70.00 | 2025 | Ozempic, Wegovy |
| Abiomed | $68.70 | 2024-2025 | Impella |
| Heartflow, INC. | $54.17 | 2023-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $51.03 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $49.24 | 2023-2024 | Definity |
| Stryker Corporation | $48.02 | 2025 | Flowtriever |
| Biotronik INC. | $24.18 | 2023 | Biomonitor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.41 | 2023 | Verquvo |
| Pfizer INC. | $20.13 | 2025 | |
| Medtronic, INC. | $18.43 | 2025 | Azure Xt Dr Mri Surescan |
| Bridgebio Pharma, INC. | $17.71 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $16.19 | 2025 | |
| Teleflex LLC | $15.69 | 2025 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anika Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.